In vitro disease models that could lead to new therapies

14 Nov 2019

New models can help researchers investigate disease development and find new treatment approaches.

PromoCell - a manufacturer of human primary cells and cell culture products - now offers cell disease models covering a wide range of diseases including diabetes type 1 and 2, respiratory diseases such as COPD and asthma, as well as cardiomyopathy disease.

In vitro disease models that could lead to new therapies

Relevant models enable experiments under physiologic conditions and are key for developing new therapies for chronic diseases. With its greater range of cell disease models, PromoCell once again underlines its role as a dedicated supporter of scientific research and innovation.

Large selection of donor cells with known disease status

“PromoCell now offers a large selection of donor cells with known disease status that are suitable for drug discovery and research applications,” says Daniel Spatz, CBO of PromoCell. These disease cell types can be cultured using PromoCell’s matching growth media to ensure optimal growth performance. “Our diseased cells feature the same specifications and undergo the same rigid quality control tests as their healthy counterparts from our human primary cell portfolio,” adds Dr. Irma Boercsoek, COO of PromoCell. The tests include cell factors marker characterization, growth performance and morphology.

Developing and testing potential treatment approaches

A cell disease model is an in vitro culture of cells isolated from a tissue donor with a known disease condition. By studying cell disease models, researchers gain insights in how diseases develop and this also enables them to look for new molecular targets for specific therapies. In addition, cell disease models can be used for testing potential treatment approaches. With its comprehensive portfolio of products and services for human cell culture, PromoCell supports scientists worldwide in advancing research and developing safer drugs.

Read More

Related news

Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment

Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment

4 Dec 2019

Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.

Read more 
Eli Lilly unveils shared innovation laboratory in San Francisco

Eli Lilly unveils shared innovation laboratory in San Francisco

3 Dec 2019

Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.

Read more 
Ground-breaking work creates novel oil-in-water nanoemulsions

Ground-breaking work creates novel oil-in-water nanoemulsions

3 Dec 2019

New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.

Read more 
UK experiences a 'baby boom' of new life sciences ventures

UK experiences a 'baby boom' of new life sciences ventures

2 Dec 2019

Unprecedented levels of investment cited as a major force driving the expansion.

Read more 
Recipharm joins the AMR Industry Alliance

Recipharm joins the AMR Industry Alliance

15 Nov 2019

Marks the latest step in the company’s ongoing efforts to engage with other organisations working to tackle antimicrobial resistance.

Read more 
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

8 Nov 2019

But personalized medicines will require new logistics and manufacturing systems.

Read more 
Recipharm launches new service to support companies with QC and analytical requirements

Recipharm launches new service to support companies with QC and analytical requirements

1 Nov 2019

Services including method development, method validation, and stability program design and implementation.

Read more 
FDA approves first  and only medicine in a new class of acute treatment for migraine

FDA approves first and only medicine in a new class of acute treatment for migraine

15 Oct 2019

The approval of Eli Lilly's Reyvow represents the first new class of acute migraine treatment approved by the FDA in more than two decades.

Read more 
Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio

Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio

14 Oct 2019

Company's Ibex Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months.

Read more 
Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more